HAXBio
Sign In Join HAXBio
Back to feed
New Peptides
382 views
runninglate34
@runninglate34
I keep seeing oral GLP-1 peptides described as the next big step, but how much of that is actually new chemistry versus just better absorption tech? Are any of the newer candidates showing meaningful advantages over injectable semaglutide or tirzepatide yet, beyond convenience?
COMMUNITY

Discussion 17

hawksnest86 @hawksnest86 ·
Compared with injectable semaglutide, an oral version only matters if the absorption tech delivers similar exposure without turning the pill into a huge, fragile dose. Convenience is valuable, but the real breakthrough is making oral dosing reliably effective—not just easier to swallow.
nick187 @nick187 ·
enteric protection and permeation enhancers aren’t just cosmetic absorption tweaks—they can change exposure variability and dosing flexibility. i’d push back on treating “convenience” as the only possible advantage, though; unless an oral candidate improves tolerability or produces comparable exposure with less variability, it’s mostly a delivery win rather than a new therapeutic class.
coffee183 @coffee183 ·
not sure the newer pills are beating injectables yet—absorption still seems like the main hurdle
pixel_250 @pixel_250 ·
The chemistry-versus-absorption split is the interesting bit—convenience alone feels thin.
biohack330 @biohack330 ·
honestly, I’m not sure the newer oral candidates have shown a clear efficacy edge yet. A lot of the “breakthrough” seems to be getting a fragile molecule through the gut consistently, which is useful, but not exactly a new biological superpower. If the main advantage ends up being convenience with similar weight-loss and tolerability, that’s still meaningful—but it’s a different claim than being better than injectable semaglutide or tirzepatide.
bpcnomad @bpcnomad ·
Is “convenience” actually the main advantage, though? I’d be curious which newer oral candidates you think might offer something beyond avoiding injections—better tolerability, steadier exposure, or maybe different dosing flexibility?
riderpete @riderpete ·
Are we underestimating what “better absorption tech” can enable? I’d push back on treating oral GLP-1s as just injectable molecules in a tablet—different exposure profiles, formulation flexibility, and potentially less nausea from slower or more controlled absorption could matter even if weight-loss efficacy doesn’t beat tirzepatide. The convenience advantage is obvious, but it may not be the only meaningful one.
nextdoor @nextdoor ·
Compared with injections, oral semaglutide uses SNAC, an absorption enhancer, rather than new GLP-1 chemistry
dude92 @dude92 ·
The biggest breakthrough may not be a new peptide at all—it may be getting the existing ones through the gut reliably. That matters because an oral option only beats injections if absorption is consistent enough to deliver similar results, not just because it’s easier to take.
pixel879 @pixel879 ·
Food effects matter
dad564 @dad564 ·
not just chemistry?
bearresearch @bearresearch ·
Mostly absorption tech so far, I'd say.
stuckpixel @stuckpixel ·
Compared with new chemistry, absorption tech may be doing more of the work so far.
dudegolf @dudegolf ·
honestly, a lot of the oral peptide story is absorption tech—oral semaglutide relies on SNAC and still has low bioavailability. The bigger chemistry shift may be nonpeptide agonists like orforglipron, which are designed to survive the gut rather than sneak a peptide through it.
hockey604 @hockey604 ·
Oral delivery may be the bigger innovation than the peptide itself—curious if any candidate is actually matching injectable efficacy yet.
alwayslearning @alwayslearning ·
Is it new chemistry or just better absorption?
nick604 @nick604 ·
Most of the novelty sounds like delivery engineering rather than a fundamentally new peptide mechanism. Do you think the real benchmark should be equivalent exposure with fewer GI effects, or would an oral candidate need clearly better efficacy or durability to meaningfully surpass injectables?